Press coverage about Celldex Therapeutics (NASDAQ:CLDX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.0390377764121 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Celldex Therapeutics (CLDX) opened at $2.80 on Friday. The stock has a market capitalization of $380.76, a price-to-earnings ratio of -2.77 and a beta of 2.73. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $3.94.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.07. The business had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The business’s revenue for the quarter was up 77.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.29) EPS. equities analysts predict that Celldex Therapeutics will post -0.93 earnings per share for the current year.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.